O	0	6	Effect
O	7	9	of
B-intervention	10	21	anaesthetic
I-intervention	22	31	technique
O	32	34	on
B-eligibility	35	44	oestrogen
I-eligibility	45	53	receptor
I-eligibility	53	54	-
I-eligibility	54	62	negative
I-eligibility	63	69	breast
I-eligibility	70	76	cancer
I-eligibility	77	81	cell
I-eligibility	82	90	function
I-eligibility	91	93	in
I-eligibility	94	99	vitro
O	99	100	.

O	101	111	Metastatic
O	112	122	recurrence
O	123	125	is
O	126	129	the
O	130	134	main
O	135	140	cause
O	141	143	of
O	144	150	breast
O	151	157	cancer
O	157	158	-
O	158	165	related
O	166	172	deaths
O	172	173	.

O	174	180	Tumour
O	181	185	cell
O	186	199	proliferation
O	200	203	and
O	204	213	migration
O	214	217	are
O	218	225	crucial
O	226	231	steps
O	232	234	in
O	235	238	the
O	239	249	metastatic
O	250	257	process
O	257	258	.

O	259	266	Several
O	267	280	perioperative
O	281	288	factors
O	288	289	,
O	290	299	including
O	300	307	general
O	308	319	anaesthesia
O	320	323	and
O	324	330	opioid
O	331	340	analgesia
O	340	341	,
O	342	351	adversely
O	352	358	affect
O	359	365	immune
O	366	374	function
O	374	375	,
O	376	387	potentially
O	388	398	increasing
O	399	409	metastatic
O	410	420	recurrence
O	420	421	.

O	422	430	Regional
O	431	442	anaesthesia
O	442	443	-
O	443	452	analgesia
O	453	456	has
O	457	461	been
O	462	474	consistently
O	475	480	shown
O	481	483	to
O	484	493	attenuate
O	494	497	the
O	498	504	stress
O	505	513	response
O	514	516	to
O	517	524	surgery
O	524	525	,
O	526	529	and
O	530	534	also
O	535	541	reduce
O	542	548	opioid
O	549	552	and
O	553	560	general
O	561	572	anaesthesia
O	573	585	requirements
O	585	586	,
O	587	594	thereby
O	595	606	attenuating
O	607	611	this
O	612	625	perioperative
O	626	643	immunosuppression
O	643	644	.

O	645	647	We
O	648	660	investigated
O	661	664	the
O	665	671	effect
O	672	674	of
O	675	680	serum
O	681	685	from
O	686	692	breast
O	693	699	cancer
O	700	707	surgery
O	708	716	patients
O	717	720	who
O	721	729	received
O	730	739	different
O	740	751	anaesthetic
O	752	762	techniques
O	763	765	on
O	766	772	breast
O	773	779	cancer
O	780	784	cell
O	785	793	function
O	794	796	in
O	797	802	vitro
O	802	803	.

O	804	812	Patients
O	813	817	were
O	818	828	randomized
O	829	831	to
O	832	839	receive
B-intervention	840	848	propofol
I-intervention	848	849	/
I-intervention	849	862	paravertebral
I-intervention	863	874	anaesthesia
I-intervention	874	875	-
I-intervention	875	884	analgesia
O	885	886	(
O	886	894	propofol
O	894	895	/
O	895	908	paravertebral
O	908	909	,
O	910	911	n
O	911	912	=
B-intervention-participants	912	914	11
O	914	915	)
O	916	918	or
B-control	919	930	sevoflurane
I-control	931	938	general
I-control	939	950	anaesthesia
O	951	955	with
O	956	962	opioid
O	963	972	analgesia
O	973	974	(
O	974	985	sevoflurane
O	985	986	/
O	986	992	opioid
O	992	993	,
O	994	995	n
O	995	996	=
B-control-participants	996	998	11
O	998	999	)
O	999	1000	.

O	1001	1004	The
O	1005	1007	ER
O	1007	1008	-
O	1008	1016	negative
O	1017	1020	MDA
O	1020	1021	-
O	1021	1023	MB
O	1023	1024	-
O	1024	1027	231
O	1028	1032	cell
O	1033	1037	line
O	1038	1041	was
O	1042	1049	treated
O	1050	1054	with
O	1055	1062	patient
O	1063	1068	serum
O	1069	1073	from
O	1074	1078	both
O	1079	1085	groups
O	1085	1086	.

O	1087	1090	The
O	1091	1098	effects
O	1099	1101	on
O	1102	1115	proliferation
O	1116	1119	and
O	1120	1129	migration
O	1130	1134	were
O	1135	1143	measured
O	1143	1144	.

O	1145	1154	Treatment
O	1155	1161	groups
O	1162	1166	were
O	1167	1171	well
O	1172	1180	balanced
O	1181	1184	for
O	1185	1188	age
O	1188	1189	,
O	1190	1196	weight
O	1196	1197	,
O	1198	1206	surgical
O	1207	1216	procedure
O	1216	1217	,
O	1218	1221	and
O	1222	1228	cancer
O	1229	1238	pathology
O	1238	1239	.

B-outcome	1240	1244	Pain
I-outcome	1245	1251	scores
O	1252	1256	were
O	1257	1262	lower
B-outcome	1263	1265	at
I-outcome	1266	1267	1
I-outcome	1268	1271	and
I-outcome	1272	1273	2
I-outcome	1274	1275	h
O	1276	1278	in
O	1279	1282	the
O	1283	1291	propofol
O	1291	1292	/
O	1292	1305	paravertebral
O	1306	1315	analgesia
O	1316	1321	group
O	1321	1322	.

O	1323	1331	Compared
O	1332	1336	with
O	1337	1349	preoperative
O	1350	1356	values
O	1356	1357	,
B-outcome	1358	1371	proliferation
I-outcome	1372	1374	of
I-outcome	1375	1378	MDA
I-outcome	1378	1379	-
I-outcome	1379	1381	MB
I-outcome	1381	1382	-
I-outcome	1382	1385	231
I-outcome	1386	1391	cells
I-outcome	1392	1399	treated
O	1400	1404	with
O	1405	1418	postoperative
O	1419	1426	patient
O	1427	1432	serum
O	1433	1435	at
O	1436	1438	10
O	1438	1439	%
O	1440	1453	concentration
O	1454	1458	from
O	1459	1462	the
O	1463	1471	propofol
O	1471	1472	/
O	1472	1485	paravertebral
O	1486	1491	group
O	1492	1495	was
O	1496	1509	significantly
O	1510	1517	reduced
O	1518	1526	compared
O	1527	1531	with
O	1532	1535	the
O	1536	1547	sevoflurane
O	1547	1548	/
O	1548	1554	opioid
O	1555	1560	group
O	1561	1562	(
O	1562	1563	-
O	1563	1565	24
O	1565	1566	%
O	1567	1569	vs
O	1570	1572	73
O	1572	1573	%
O	1573	1574	,
O	1575	1576	P
O	1576	1577	=
O	1577	1578	0
O	1578	1579	.
O	1579	1581	01
O	1581	1582	)
O	1582	1583	.

O	1584	1589	There
O	1590	1593	was
O	1594	1596	no
O	1597	1608	significant
B-outcome	1609	1615	change
I-outcome	1616	1618	in
I-outcome	1619	1622	MDA
I-outcome	1622	1623	-
I-outcome	1623	1625	MB
I-outcome	1625	1626	-
I-outcome	1626	1629	231
I-outcome	1630	1634	cell
I-outcome	1635	1644	migration
I-outcome	1645	1650	after
I-outcome	1651	1660	treatment
O	1661	1665	with
O	1666	1673	patient
O	1674	1679	serum
O	1680	1687	between
O	1688	1691	the
O	1692	1695	two
O	1696	1702	groups
O	1702	1703	.

O	1704	1709	Serum
O	1710	1714	from
O	1715	1723	patients
O	1724	1733	receiving
O	1734	1742	propofol
O	1742	1743	/
O	1743	1756	paravertebral
O	1757	1768	anaesthesia
O	1769	1772	for
O	1773	1779	breast
O	1780	1786	cancer
O	1787	1794	surgery
O	1795	1804	inhibited
O	1805	1818	proliferation
O	1818	1819	,
O	1820	1823	but
O	1824	1827	not
O	1828	1837	migration
O	1837	1838	,
O	1839	1841	of
O	1842	1844	ER
O	1844	1845	-
O	1845	1848	MDA
O	1848	1849	-
O	1849	1851	MB
O	1851	1852	-
O	1852	1855	231
O	1856	1861	cells
O	1862	1864	in
O	1865	1870	vitro
O	1870	1871	,
O	1872	1874	to
O	1875	1876	a
O	1877	1884	greater
O	1885	1891	extent
O	1892	1896	than
O	1897	1901	that
O	1902	1906	from
O	1907	1915	patients
O	1916	1925	receiving
O	1926	1937	sevoflurane
O	1937	1938	/
O	1938	1944	opioid
O	1945	1956	anaesthesia
O	1956	1957	-
O	1957	1966	analgesia
O	1966	1967	.

O	1968	1972	This
O	1973	1980	implies
O	1981	1985	that
O	1986	1997	anaesthetic
O	1998	2007	technique
O	2008	2014	alters
O	2015	2018	the
O	2019	2024	serum
O	2025	2034	molecular
O	2035	2041	milieu
O	2042	2044	in
O	2045	2049	ways
O	2050	2054	that
O	2055	2058	may
O	2059	2065	affect
O	2066	2072	breast
O	2073	2079	cancer
O	2080	2084	cell
O	2085	2093	function
O	2093	2094	,
O	2095	2103	possibly
O	2104	2106	by
O	2107	2115	altering
O	2116	2127	anaesthetic
O	2128	2131	and
O	2132	2138	opioid
O	2139	2143	drug
O	2144	2158	administration
O	2159	2162	and
O	2163	2172	resultant
O	2173	2177	pain
O	2178	2184	scores
O	2184	2185	.
